Stock Markets February 19, 2026

Hims & Hers to Buy Australia’s Eucalyptus in Deal Worth Up to $1.15 Billion

U.S. telehealth firm moves to expand personalized care internationally; cash payment and regulatory headwinds highlighted

By Ajmal Hussain
Hims & Hers to Buy Australia’s Eucalyptus in Deal Worth Up to $1.15 Billion

Hims & Hers Health announced it will acquire Australian digital health company Eucalyptus in a transaction valued at up to $1.15 billion. The purchase is designed to extend Hims & Hers' personalized care offerings into Australia and Japan and to strengthen access in the United Kingdom, Germany and Canada through regional partnerships. The deal includes an initial cash payment of $240 million at closing and is targeted to complete in the middle of calendar year 2026. Hims & Hers is also contending with a lawsuit from Novo Nordisk after an FDA action prompted the company to withdraw a $49 copy of the weight-loss drug Wegovy.

Key Points

  • Deal value up to $1.15 billion to acquire Australian digital health operator Eucalyptus.
  • Acquisition provides Hims & Hers with a direct foothold in Australia and Japan, and extends reach in the UK, Germany and Canada via regional partnerships.
  • Eucalyptus operates consumer brands such as Juniper and Pilot and has served more than 775,000 customers; about $240 million is payable in cash on closing, with completion expected mid calendar year 2026.

Hims & Hers Health said on Feb 19 that it will acquire Australian digital health operator Eucalyptus in a transaction valued at up to $1.15 billion. The deal is part of Hims & Hers' push to broaden its personalized care business into new international markets.

According to the announcement, the acquisition would provide Hims & Hers with a direct presence in Australia and Japan while also bolstering its footprint in the United Kingdom, Germany and Canada through partnerships with established regional operators. Eucalyptus runs several consumer-facing brands, including the weight-loss program Juniper and the men's telehealth brand Pilot, and Hims & Hers said the business has served more than 775,000 customers.

Financial terms disclosed include approximately $240 million payable in cash at the time the transaction closes. The company said the acquisition is expected to close during the middle of calendar year 2026.

The announcement comes as Hims & Hers faces a legal dispute with Novo Nordisk. The suit follows regulatory action by the U.S. Food and Drug Administration that led Hims & Hers to abruptly withdraw a newly launched $49 copy of Novo Nordisk's weight-loss drug Wegovy. Hims & Hers flagged the lawsuit as part of the same public disclosure that detailed the planned acquisition.

For Hims & Hers, acquiring Eucalyptus appears aimed at accelerating access to international consumers via existing digital brands and operator partnerships. Eucalyptus' consumer programs and telehealth offerings represent products and channels that Hims & Hers said will complement its personalized care strategy in markets outside the United States.

The timetable and structure described in the announcement leave open the usual uncertainties associated with closing large cross-border deals. The company identified the mid-2026 closing window and the initial cash component, but did not elaborate further on the transaction mechanics in the disclosure.


Contextual note - The acquisition announcement ties together Hims & Hers' international expansion plans and the immediate legal and regulatory challenges it has disclosed. The company reported the customer count for Eucalyptus and specified brands that will transfer to Hims & Hers upon completion of the deal.

Risks

  • Legal risk from an ongoing lawsuit filed by Novo Nordisk related to Hims & Hers' withdrawn $49 copy of the Wegovy weight-loss drug - impacts the pharmaceutical and digital health sectors.
  • Regulatory pressure from the U.S. Food and Drug Administration, which previously prompted the withdrawal of the product, creating uncertainty for Hims & Hers' weight-loss offerings.
  • Timing and execution uncertainty around a cross-border acquisition expected to close in mid calendar year 2026 - impacts deal certainty for investors and partners in digital health markets.

More from Stock Markets

FERC Clears Path for Blackstone-TXNM Energy Deal, Removing Major Federal Hurdle Feb 20, 2026 Vanda Gains FDA Nod for BYSANTI, Shares Spike as Company Secures Second Approval in Weeks Feb 20, 2026 Supreme Court Reviews Broad Array of Trump-Era Policies Across Trade, Immigration and Federal Workforce Feb 20, 2026 UBS Lifts Corning Price Target to $160 Citing Surge in AI Data Center Fiber Demand Feb 20, 2026 Toymakers Weigh Options After Supreme Court Nixes Emergency Tariffs Feb 20, 2026